ClinicalTrials.gg

Program

Cisplatin

Also written as “cisplatin”, “docetaxel and cisplatin” and “Pemetrexed/Cisplatin”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms · Stomach Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms, led by 21 companies.

Furthest: phase 4, since Sep 12, 2005110 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly490 open or runningphase 3since Sep 12, 2005Jan 10, 2003none ahead
Sanofi150 open or runningphase 4since Oct 13, 2008Jun 6, 2001none ahead
Hoffmann-La Roche130 open or runningphase 3since Aug 18, 2009Apr 17, 2008none ahead
Bristol-Myers Squibb80 open or runningphase 3since Jun 14, 2006Jun 14, 2006none ahead
Pfizer60 open or runningphase 3since Jan 21, 2000Jan 21, 2000none ahead
Otsuka30 open or runningphase 3since Jun 30, 2005Nov 10, 2003none ahead
Sino Biopharmaceutical20 open or runningphase 3since Jul 17, 2018Jul 17, 2018none ahead
academy-military-medical-science-china10 open or runningphase 2since Jul 14, 2008Jul 14, 2008none ahead
allarity-therapeutics10 open or runningphase 2since May 1, 2013May 1, 2013none ahead
Bayer10 open or runningphase 2since Jul 27, 2006Jul 27, 2006none ahead
cbsbioscience10 open or runningphase 2since Nov 10, 2016Nov 10, 2016none ahead
coherus-oncology-inc11 open or runningphase 4since Jun 10, 2024Jun 10, 2024Dec 2027phase 4 · NCT06457503
CSPC Pharmaceutical Group10 open or runningphase 2since Dec 11, 2017Dec 11, 2017none ahead
Eisai10 open or runningphase 2since May 17, 2010May 17, 2010none ahead
eleison-pharmaceuticals-llc10 open or runningphase 2since Jul 20, 2012Jul 20, 2012none ahead
healthcare-global-enterprise-ltd10 open or runningphase 2since Sep 29, 2016Sep 29, 2016none ahead
hope-cancer-institute-inc10 open or runningphase 2since Nov 1, 1999Nov 1, 1999none ahead
jiangsu-healthy-life-innovation-medical-technology-co-ltd11 open or runningno phasesince Sep 20, 2024Sep 20, 2024none ahead
NovoCure10 open or runningphase 2since Mar 19, 2015Mar 19, 2015none ahead
Sarah Cannon Research Institute10 open or runningphase 2since Jan 9, 2009Jan 9, 2009none ahead
zivena10 open or runningphase 2since May 11, 2004May 11, 2004none ahead

Also a collaborator on its studies: AstraZeneca, Merck, Ono Pharmaceutical, parexel, Daiichi Sankyo, Halozyme Therapeutics, biolinerx-ltd, quintiles-inc, pharmabio-development-inc, Takeda and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jun 21, 2007.

  1. Dec 16, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT02998528 · 505 enrolled · United States, Argentina, Brazil and more
  2. Jan 27, 2017Phase 3 study in Urothelial CancerBristol-Myers Squibb · NCT03036098 · 1,314 enrolled · United States, Argentina, Australia and more
  3. May 4, 2017Phase 3 study in Various Advanced CancerBristol-Myers Squibb · NCT03143153 · 970 enrolled · United States, Argentina, Australia and more
  4. Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
  5. Nov 17, 2017Phase 3 study in Squamous Cell Carcinoma of Head and NeckBristol-Myers Squibb · NCT03349710 · 74 enrolled · United States, France, Italy and more
  6. Dec 11, 2017CSPC Pharmaceutical Group's first study: phase 2 study in Poorly Differentiated Thyroid CarcinomaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03387943 · 30 enrolled · China
  7. Jul 17, 2018Sino Biopharmaceutical's first study: phase 3 study in Nasopharyngeal CarcinomaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03601975 · 336 enrolled · China
  8. Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellHoffmann-La Roche · NCT03869190 · 272 enrolled · United States, France, Greece and more
  9. Nov 4, 2020Phase 2 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04622228 · 56 enrolled · China
  10. Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
  11. Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaSino Biopharmaceutical · NCT05834543 · 34 enrolled · China
  12. Jun 10, 2024coherus-oncology-inc's first study: phase 4 study in Nasopharyngeal NeoplasmsNew to coherus-oncology-inccoherus-oncology-inc · NCT06457503 · 100 planned · United States, Canada
  13. Sep 20, 2024jiangsu-healthy-life-innovation-medical-technology-co-ltd's first study: no phase study in Biliary Tract NeoplasmsNew to jiangsu-healthy-life-innovation-medical-technology-co-ltdjiangsu-healthy-life-innovation-medical-technology-co-ltd · NCT06611345 · 60 planned · China
  14. Oct 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT06624059 · 11 enrolled · Australia, Brazil, Chile and more

Ahead

  1. Dec 2027Primary completion: phase 4 study in Nasopharyngeal Neoplasmscoherus-oncology-inc · NCT06457503

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 110 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06624059Carcinoma, Non-Small-Cell Lung · Australia, Brazil, Chile and more3CompletedHoffmann-La RocheJul 31, 202611
NCT06611345Biliary Tract Neoplasms · China–Recruitingjiangsu-healthy-life-innovation-medical-technology-co-ltdOct 30, 202660
NCT06457503Nasopharyngeal Neoplasms · United States, Canada4Recruitingcoherus-oncology-incDec 2027100
NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China2TerminatedSino BiopharmaceuticalOct 23, 202434
NCT05136677Mesothelioma, Malignant · China2CompletedBristol-Myers SquibbNov 12, 2025102
NCT04622228Small Cell Lung Carcinoma · China2CompletedHoffmann-La RocheJun 21, 202256
NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more2TerminatedHoffmann-La RocheOct 8, 2025272
NCT03601975Nasopharyngeal Carcinoma · China3UNKNOWNSino BiopharmaceuticalJul 30, 2020336
NCT03387943Poorly Differentiated Thyroid Carcinoma · China2UNKNOWNCSPC Pharmaceutical GroupDec 31, 201830
NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more3CompletedBristol-Myers SquibbOct 14, 201974
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedHoffmann-La RocheOct 9, 2025219
NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJan 18, 2021970
NCT03036098Urothelial Cancer · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbAug 30, 20241,314
NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3CompletedBristol-Myers SquibbSep 8, 2021505
NCT02967887Hepatocellular Carcinoma Non-Resectable · Korea, Republic of2UNKNOWNcbsbioscienceOct 201896
NCT02985255Tongue Neoplasms · India2UNKNOWNhealthcare-global-enterprise-ltdJun 201730
NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more3CompletedHoffmann-La RocheAug 31, 20221,213
NCT02608073Nasopharyngeal Neoplasms · Hong Kong, Indonesia, Malaysia and more2CompletedHoffmann-La RocheNov 200945
NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbOct 25, 20242,747
NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more2CompletedNovoCureApr 201882
NCT02061631Squamous Cell Carcinoma of Head and Neck · Pakistan2CompletedSanofiJul 201535
NCT02006667Urologic Neoplasms · Germany2CompletedHoffmann-La RocheJan 201013
NCT01911598Head and Neck Neoplasms · United States, Belgium1CompletedHoffmann-La RocheJun 22, 201724
NCT01861496Prostatic Neoplasms · Denmark2Completedallarity-therapeuticsOct 202150
NCT01650090Osteosarcoma · United States2Completedeleison-pharmaceuticals-llcNov 201828
NCT01606748Carcinoma, Non-Small-Cell Lung · United States2CompletedEli LillyJun 201335
NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more3TerminatedHoffmann-La RocheFeb 2015296
NCT01285557Stomach Neoplasms · United States, Argentina, Belgium and more3TerminatedOtsukaAug 15, 2014361
NCT01266512Lung Neoplasms · Hong Kong2CompletedSanofiMar 201434
NCT01165021Carcinoma, Non-Small-Cell Lung · Italy2CompletedEli LillyJul 201319
NCT01126749Urinary Bladder Neoplasms · United States, Germany, Netherlands and more2TerminatedEisaiMay 8, 201592
NCT01109524Lung Neoplasms · United States, Canada, Puerto Rico2CompletedEli LillySep 201272
NCT01099358Head and Neck Neoplasms · United States, Canada2CompletedEli LillyOct 201547
NCT01087970Head and Neck Neoplasms · United States2CompletedEli LillyAug 201369
NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico2CompletedEli LillyAug 2013187
NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more2CompletedEli LillyFeb 201266
NCT01038661Lung Neoplasms · China3CompletedSanofiAug 2012375
NCT01017874Carcinoma, Non-Small-Cell Lung · Hong Kong, Korea, Republic of, Singapore and more3CompletedEli LillyApr 2013236
NCT01004250Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Italy and more2CompletedEli LillyNov 2012109
NCT01000480Carcinoma, Non-Small-Cell Lung · France, Germany, Italy and more2CompletedEli LillyJan 201390
NCT00995293Head and Neck Neoplasms · China3CompletedSanofiJan 26, 2018240
NCT00961415Non-Squamous Non-Small Cell Lung Cancer · France, Germany, Greece and more3CompletedHoffmann-La RocheMay 2011376
NCT00887549Carcinoma, Non-Small-Cell Lung · Ireland, United Kingdom2CompletedEli LillyJul 201070
NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more2CompletedEli LillyMay 2011113
NCT00821327Urothelial Cancer · United States2CompletedSarah Cannon Research InstituteAug 201236
NCT00789373Carcinoma, Non-Small-Cell Lung · Australia, Belgium, Finland and more3CompletedEli LillyJun 2010939
NCT00776698Non-Squamous Non-Small Cell Lung Cancer · Netherlands, United Kingdom1CompletedHoffmann-La RocheFeb 20101
NCT00773188Non-Squamous Non-Small Cell Lung Cancer · Canada1CompletedHoffmann-La RocheOct 20106
NCT00772863Ovarian Neoplasms · Turkey2CompletedSanofiJun 200837
NCT00772681Head and Neck Neoplasms · Turkey4CompletedSanofiMar 200857
NCT00717951Advanced Breast Cancer2UNKNOWNacademy-military-medical-science-chinaDec 2009120
NCT00661778Carcinoma, Non-Small-Cell Lung · Spain2CompletedHoffmann-La RocheJul 201150
NCT00555672Stomach Neoplasms · Spain1CompletedPfizerDec 200934
NCT00555620Stomach Neoplasms · Korea, Republic of1CompletedPfizerAug 201076
NCT00553696Stomach Neoplasms · Japan1CompletedPfizerJul 200927
NCT00528619Neoplasms · United States, Canada1CompletedPfizerApr 201096
NCT00496275Carcinoma, Non-Small-Cell Lung1CompletedSanofi17
NCT00491127Lymphoma, Non-Hodgkin · Spain2CompletedEli Lilly10
NCT00490880Urinary Bladder Neoplasms · Poland2CompletedEli Lilly2
NCT00490659Carcinoma, Non-Small-Cell Lung · Poland2CompletedEli Lilly13

How it is read

Names in the registry

  • “Cisplatin”, 86 entries
  • “cisplatin”, 51 entries
  • “docetaxel and cisplatin”, 3 entries
  • “Pemetrexed/Cisplatin”, 2 entries
  • “CISPLATIN”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.